Five-Year Follow-Up of ZUMA-3: A Phase 1/2 Study of Brexucabtagene Autoleucel for the Treatment of Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Olalekan O. Oluwole, Armin Ghobadi, Ryan D. Cassaday, Jae H. Park, Roch Houot, Aaron C. Logan, Nicolas Boissel, Thibaut Leguay, Michael R. Bishop, Max S. Topp, Kristen M. O’Dwyer, Maria R. Baer, Gary J. Schiller, Mehrdad Abedi, Monique C. Minnema, Patrick Stiff, Lang Zhou, Sabina Adhikary, Rita Damico Khalid, Bijal D. Shah

Open source

DOI: 10.1016/j.jtct.2026.11.003
Published: 2026-11
Container: Transplantation and Cellular Therapy
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtct.2026.11.003,
  title = {Five-Year Follow-Up of ZUMA-3: A Phase 1/2 Study of Brexucabtagene Autoleucel for the Treatment of Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia},
  author = {Olalekan O. Oluwole and Armin Ghobadi and Ryan D. Cassaday and Jae H. Park and Roch Houot and Aaron C. Logan and Nicolas Boissel and Thibaut Leguay and Michael R. Bishop and Max S. Topp and Kristen M. O’Dwyer and Maria R. Baer and Gary J. Schiller and Mehrdad Abedi and Monique C. Minnema and Patrick Stiff and Lang Zhou and Sabina Adhikary and Rita Damico Khalid and Bijal D. Shah},
  year = {2026},
  journal = {Transplantation and Cellular Therapy},
  doi = {10.1016/j.jtct.2026.11.003},
  url = {https://doi.org/10.1016/j.jtct.2026.11.003}
}

RIS

TY  - JOUR
TI  - Five-Year Follow-Up of ZUMA-3: A Phase 1/2 Study of Brexucabtagene Autoleucel for the Treatment of Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
AU  - Olalekan O. Oluwole
AU  - Armin Ghobadi
AU  - Ryan D. Cassaday
AU  - Jae H. Park
AU  - Roch Houot
AU  - Aaron C. Logan
AU  - Nicolas Boissel
AU  - Thibaut Leguay
AU  - Michael R. Bishop
AU  - Max S. Topp
AU  - Kristen M. O’Dwyer
AU  - Maria R. Baer
AU  - Gary J. Schiller
AU  - Mehrdad Abedi
AU  - Monique C. Minnema
AU  - Patrick Stiff
AU  - Lang Zhou
AU  - Sabina Adhikary
AU  - Rita Damico Khalid
AU  - Bijal D. Shah
PY  - 2026
JO  - Transplantation and Cellular Therapy
DO  - 10.1016/j.jtct.2026.11.003
UR  - https://doi.org/10.1016/j.jtct.2026.11.003
ER  -

APA

Oluwole, O. O., Ghobadi, A., Cassaday, R. D., Park, J. H., Houot, R., Logan, A. C., Boissel, N., Leguay, T., Bishop, M. R., Topp, M. S., O’Dwyer, K. M., Baer, M. R., Schiller, G. J., Abedi, M., Minnema, M. C., Stiff, P., Zhou, L., Adhikary, S., Khalid, R. D., & Shah, B. D. (2026). Five-Year Follow-Up of ZUMA-3: A Phase 1/2 Study of Brexucabtagene Autoleucel for the Treatment of Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy. https://doi.org/10.1016/j.jtct.2026.11.003

Source records

crossref · retrieved 2026-11-08T16:47:20.796Z